AU2022325771A1 - Heterocyclic compounds and methods of use - Google Patents

Heterocyclic compounds and methods of use Download PDF

Info

Publication number
AU2022325771A1
AU2022325771A1 AU2022325771A AU2022325771A AU2022325771A1 AU 2022325771 A1 AU2022325771 A1 AU 2022325771A1 AU 2022325771 A AU2022325771 A AU 2022325771A AU 2022325771 A AU2022325771 A AU 2022325771A AU 2022325771 A1 AU2022325771 A1 AU 2022325771A1
Authority
AU
Australia
Prior art keywords
fluoro
methoxy
pyrimidin
pyrido
pyrrolizin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022325771A
Other languages
English (en)
Inventor
Ning Chen
Josephine ESHON
Brian Alan Lanman
Kexue Li
Xiaofen Li
Yunxiao Li
Francesco Manoni
Jose Medina
Primali NAVARATNE
Liping Pettus
Rene Rahimoff
Huan RUI
John Stellwagen
Ryan Paul Wurz
Michael M. YAMANO
Wei Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2022325771A1 publication Critical patent/AU2022325771A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022325771A 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use Pending AU2022325771A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163231543P 2021-08-10 2021-08-10
US63/231,543 2021-08-10
US202163289579P 2021-12-14 2021-12-14
US63/289,579 2021-12-14
PCT/US2022/039971 WO2023018812A1 (en) 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use

Publications (1)

Publication Number Publication Date
AU2022325771A1 true AU2022325771A1 (en) 2024-02-15

Family

ID=85201014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022325771A Pending AU2022325771A1 (en) 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use

Country Status (7)

Country Link
EP (1) EP4384160A4 (https=)
JP (1) JP2024532734A (https=)
AU (1) AU2022325771A1 (https=)
CA (1) CA3228310A1 (https=)
MX (1) MX2024001893A (https=)
TW (1) TW202330529A (https=)
WO (1) WO2023018812A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
EP4436571A4 (en) * 2021-11-24 2025-10-15 Merck Sharp & Dohme Llc SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CA3247639A1 (en) 2022-05-06 2023-11-09 PAQ Therapeutics Inc. CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
CR20240508A (es) 2022-05-19 2024-12-20 Genentech Inc Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4540244A1 (en) * 2022-06-15 2025-04-23 Mirati Therapeutics, Inc. Prodrugs of pan-kras inhibitors
EP4549439A1 (en) * 2022-07-01 2025-05-07 Suzhou Zelgen Biopharmaceutical Co., Ltd. Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024012519A1 (zh) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Pan-kras抑制剂
WO2024041606A1 (zh) * 2022-08-24 2024-02-29 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
TW202430179A (zh) 2022-11-21 2024-08-01 美商樹線生物科學公司 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025038936A1 (en) 2023-08-17 2025-02-20 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
CN121941690A (zh) 2023-10-03 2026-04-28 Paq医疗公司 Kras蛋白水解靶向嵌合体
TW202529804A (zh) 2023-10-06 2025-08-01 美商安進公司 用於癌症治療的組合療法
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202602882A (zh) * 2024-03-14 2026-01-16 美商安進公司 作為ｋｒａｓ調節劑的大環化合物及其用途
WO2025194054A1 (en) * 2024-03-14 2025-09-18 Amgen Inc. Spirocyclic compounds as modulators of kras and uses thereof
WO2025228384A1 (en) * 2024-04-30 2025-11-06 Hutchmed Limited Antibody-drug conjugates and use thereof
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
EP3908283A4 (en) * 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) * 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
JP2023553492A (ja) * 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
CN117222650A (zh) * 2021-04-30 2023-12-12 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途
BR112023024906A2 (pt) * 2021-05-28 2024-02-15 Redx Pharma Plc Compostos

Also Published As

Publication number Publication date
JP2024532734A (ja) 2024-09-10
EP4384160A1 (en) 2024-06-19
TW202330529A (zh) 2023-08-01
MX2024001893A (es) 2024-02-29
CA3228310A1 (en) 2023-02-16
WO2023018812A1 (en) 2023-02-16
EP4384160A4 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
WO2023018812A1 (en) Heterocyclic compounds and methods of use
EP4479398A1 (en) Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
WO2023018810A1 (en) Heterocyclic compounds and methods of use
EP4329888A1 (en) 2-aminobenzothiazole compounds and methods of use thereof
TW202321242A (zh) 雜環化合物及使用方法
US20250163064A1 (en) Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins
WO2022232331A1 (en) Heterocyclic compounds and methods of use
EP4598921A1 (en) Macrocyclic kras inhibitors and methods of use
WO2025136346A1 (en) Indazole containing compounds and methods of use
CN117881397A (zh) 杂环化合物及使用方法
US20250034167A1 (en) Heterocyclic compounds and methods of use
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
CN117897159A (zh) 杂环化合物及使用方法
CN117835976A (zh) 杂环化合物及使用方法